NASDAQ:RLMD Relmada Therapeutics (RLMD) Stock Price, News & Analysis → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free RLMD Stock Alerts $3.53 -0.27 (-7.11%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$3.53▼$3.8850-Day Range$3.53▼$6.4052-Week Range$2.36▼$7.22Volume79,440 shsAverage Volume105,220 shsMarket Capitalization$106.51 millionP/E RatioN/ADividend YieldN/APrice Target$25.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Relmada Therapeutics alerts: Email Address Relmada Therapeutics MarketRank™ Stock AnalysisAnalyst Rating0.00 Rating ScoreUpside/Downside608.2% Upside$25.00 Price TargetShort InterestBearish5.44% of Shares Sold ShortDividend StrengthN/ASustainability-1.45Upright™ Environmental ScoreNews Sentiment0.81Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.53) to ($2.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.06 out of 5 starsMedical Sector390th out of 921 stocksPharmaceutical Preparations Industry173rd out of 428 stocks 2.0 Analyst's Opinion Amount of Analyst CoverageRelmada Therapeutics has received no research coverage in the past 90 days.Read more about Relmada Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.44% of the outstanding shares of Relmada Therapeutics have been sold short.Short Interest Ratio / Days to CoverRelmada Therapeutics has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Relmada Therapeutics has recently decreased by 4.09%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRelmada Therapeutics does not currently pay a dividend.Dividend GrowthRelmada Therapeutics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRelmada Therapeutics has received a 66.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Clinical research services for mood disorders" product. See details.Environmental SustainabilityThe Environmental Impact score for Relmada Therapeutics is -1.45. Previous Next 2.7 News and Social Media Coverage News SentimentRelmada Therapeutics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Relmada Therapeutics this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Relmada Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders18.00% of the stock of Relmada Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.24% of the stock of Relmada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Relmada Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Relmada Therapeutics are expected to grow in the coming year, from ($3.53) to ($2.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relmada Therapeutics is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relmada Therapeutics is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelmada Therapeutics has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Relmada Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Relmada Therapeutics Stock (NASDAQ:RLMD)Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.Read More RLMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RLMD Stock News HeadlinesMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Relmada Therapeutics on Strong Clinical Trials and Financial FootingMay 10, 2024 | markets.businessinsider.comBuy Rating for Relmada Therapeutics Supported by Strong Clinical Pipeline and Financial StabilityMay 11, 2024 | Crypto 101 Media (Ad)The Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.May 9, 2024 | finance.yahoo.comQ1 2024 Relmada Therapeutics Inc Earnings CallMay 8, 2024 | msn.comRLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q1 2024May 8, 2024 | prnewswire.comRelmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 6, 2024 | prnewswire.comRelmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024April 16, 2024 | finance.yahoo.comRELMADA THERAPEUT.DL-,001 (4E2.F)May 11, 2024 | Crypto 101 Media (Ad)The Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.March 21, 2024 | seekingalpha.comRelmada Therapeutics: Run Up Into Results May Resume Following This DropMarch 21, 2024 | markets.businessinsider.comOptimistic Buy Rating for Relmada Therapeutics Amidst Strong Phase 3 Trial Prospects and Financial StabilityMarch 20, 2024 | finance.yahoo.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | finanznachrichten.deRelmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 20, 2024 | finance.yahoo.comQ4 2023 Relmada Therapeutics Inc Earnings CallMarch 19, 2024 | investorplace.comRLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023March 19, 2024 | benzinga.comRecap: Relmada Therapeutics Q4 EarningsMarch 19, 2024 | finance.yahoo.comRelmada Therapeutics Inc Reports Full-Year and Q4 2023 Financial ResultsMarch 19, 2024 | prnewswire.comRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 19, 2024 | msn.comOptions Volatility and Implied Earnings Moves Today, March 19, 2024March 18, 2024 | msn.comRelmada Therapeutics FY 2023 Earnings PreviewMarch 16, 2024 | finance.yahoo.comRLMD Apr 2024 2.500 putMarch 5, 2024 | prnewswire.comRelmada Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceFebruary 13, 2024 | investing.comRelmada Therapeutics Inc (RLMD)February 5, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Immunocore Holdings (IMCR), Thermo Fisher (TMO)February 4, 2024 | thestreet.comRelmada Therapeutics Inc.February 2, 2024 | msn.comRelmada Therapeutics And 2 Other Penny Stocks Insiders Are BuyingFebruary 1, 2024 | marketwatch.comRelmada Therapeutics Shares Hit 52-Week High After Execs Buy SharesSee More Headlines Receive RLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/19/2024Today5/11/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RLMD CUSIPN/A CIK1553643 Webwww.relmada.com Phone(786) 629-1376FaxN/AEmployees20Year Founded2004Price Target and Rating Average Stock Price Target$25.00 High Stock Price Target$25.00 Low Stock Price Target$25.00 Potential Upside/Downside+608.2%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($3.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-98,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-102.09% Return on Assets-91.30% Debt Debt-to-Equity RatioN/A Current Ratio6.82 Quick Ratio8.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.39 per share Price / Book1.48Miscellaneous Outstanding Shares30,170,000Free Float24,743,000Market Cap$106.50 million OptionableOptionable Beta0.27 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Sergio Traversa M.B.A. (Age 64)Pharm.D., CEO & Director Comp: $1.79MMr. Maged S. Shenouda M.B.A. (Age 60)R.Ph., Chief Financial Officer Comp: $1.01MMr. Charles S. Ence CPA (Age 59)M.B.A., Chief Accounting & Compliance Officer Comp: $995.03kDr. Paolo Manfredi M.D. (Age 62)Ph.D., Chief Scientific Officer Ms. Gina DiGuglielmoVP & Head of Clinical OperationsDr. Marco Pappagallo M.D. (Age 65)Chief Clinical Officer Mr. John HixonHead of CommercialDr. Andrew CutlerSenior Clinical Development AdvisorDr. Richard M. Mangano (Age 74)Consultant More ExecutivesKey CompetitorsRezoluteNASDAQ:RZLTSocietal CDMONASDAQ:SCTLOptiNoseNASDAQ:OPTNCellectar BiosciencesNASDAQ:CLRBPMV PharmaceuticalsNASDAQ:PMVPView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 54,100 shares on 5/10/2024Ownership: 4.165%State Board of Administration of Florida Retirement SystemBought 15,100 shares on 5/9/2024Ownership: 0.050%SG Americas Securities LLCBought 11,320 shares on 5/7/2024Ownership: 0.038%GSA Capital Partners LLPSold 81,252 shares on 5/3/2024Ownership: 0.342%Guild Investment Management Inc.Sold 21,100 shares on 4/26/2024Ownership: 0.633%View All Insider TransactionsView All Institutional Transactions RLMD Stock Analysis - Frequently Asked Questions What is Relmada Therapeutics' stock price target for 2024? 0 brokerages have issued twelve-month price objectives for Relmada Therapeutics' stock. Their RLMD share price targets range from $25.00 to $25.00. On average, they predict the company's share price to reach $25.00 in the next twelve months. This suggests a possible upside of 608.2% from the stock's current price. View analysts price targets for RLMD or view top-rated stocks among Wall Street analysts. How have RLMD shares performed in 2024? Relmada Therapeutics' stock was trading at $4.14 at the start of the year. Since then, RLMD shares have decreased by 14.7% and is now trading at $3.53. View the best growth stocks for 2024 here. When is Relmada Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our RLMD earnings forecast. How were Relmada Therapeutics' earnings last quarter? Relmada Therapeutics, Inc. (NASDAQ:RLMD) announced its quarterly earnings data on Tuesday, March, 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.88) by $0.04. What ETF holds Relmada Therapeutics' stock? AdvisorShares Psychedelics ETF holds 77,022 shares of RLMD stock, representing 4.31% of its portfolio. Who are Relmada Therapeutics' major shareholders? Relmada Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.17%), Parsons Capital Management Inc. RI (3.23%), Guild Investment Management Inc. (0.63%), GSA Capital Partners LLP (0.34%), State Board of Administration of Florida Retirement System (0.05%) and SG Americas Securities LLC (0.04%). Insiders that own company stock include Cedric O'gorman, Charles J Casamento, Chuck Ence, Maged Shenouda, Paul Edward Kelly and Sergio Traversa. View institutional ownership trends. How do I buy shares of Relmada Therapeutics? Shares of RLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RLMD) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
